Sanofi Unruffled By JAK Threat To Dupixent

As Blockbuster Hits €5.25bn In 2021 Sales

CEO Paul Hudson tells Scrip that in an atopic dermatitis market that has a standard of care like Dupixent, "it's hard to justify the role of a JAK unless somebody has, frankly, failed everything else."  

Sanofi logo
The French major's new logo • Source: Sanofi

As Sanofi posts yet another stellar set of sales figures for its autoimmune mega-blockbuster Dupixent, CEO Paul Hudson has told Scrip that growth is set to keep soaring despite the arrival of competition in the US from oral JAK inhibitors in its key indication of atopic dermatitis.

The French major's fourth-quarter revenues of €9.99bn (+4.1%) were dominated yet again by Regeneron Pharmaceuticals, Inc.-partnered Dupixent (dupilumab) which...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.